Clinical Trials
46 trialsErlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
Hunan Province Tumor Hospital
ROME
Fondazione per la Medicina Personalizzata
BRISK
Asan Medical Center
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
ERLO-XIB
Tata Memorial Hospital
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
National Cancer Center, Korea
AvaTa
National Cancer Center, Korea
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
ANSWER
The First Affiliated Hospital of Guangzhou Medical University
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
BRILLIANT
National Taiwan University Hospital
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Sichuan Cancer Hospital and Research Institute
ML22774
Ludwig-Maximilians - University of Munich
High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
Anhui Medical University
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
University of Kansas Medical Center
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Tianjin Medical University Cancer Institute and Hospital
RT Plus EGFR-TKI for Wild-type NSCLC
Hangzhou Cancer Hospital
Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
First Affiliated Hospital of Kunming Medical University
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
Fudan University
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
NSCLC EGFR TKI
Sun Yat-sen University
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
Sun Yat-sen University
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
Taipei Veterans General Hospital, Taiwan
TRACTS
Wu Jieping Medical Foundation
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
MedicalLogic
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in â…¢b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Sun Yat-sen University
Oncology
National Taiwan University Hospital
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
ROLE
Wu Jieping Medical Foundation
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
Chinese Lung Cancer Surgical Group
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
National Cancer Center, Korea
Dux
Austin Health
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
Chinese PLA General Hospital
The Continuation of Erlotinib
Samsung Medical Center
RT0901
Zhejiang Cancer Hospital
ERLOPET
Lung Cancer Group Cologne
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
National Cancer Institute (NCI)
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen
Hospital Arnau de Vilanova
Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Universitair Ziekenhuis Brussel
TIE
LungenClinic Grosshansdorf
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
GuangdongPPH
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer
Hospital of Navarra
Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
Grupo Gallego de Cancer de Pulmon
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Universitair Ziekenhuis Brussel